



ISSN 2395-650X

International Journal of
Life Sciences Biotechnology Pharma Sciences

IJLBPS

www.ijlbps.org

E-mail: editorijlbps@gmail.com editor@ijlbps.org

Development and Validation of RP-HPLC method for Simultaneous estimation of combined drug in Pharmaceutical formulation

J.VIJAY

Abstract

The design, development, standardization, and quality control of medical goods are unattainable without analytical methods. Although just a first effort was undertaken in this study, validated analytical techniques for the determination of a single or mixed dose form have been developed. Methods for the quantitative and qualitative analysis of nebivolol HCl and telmisartan were validated in accordance with ICH guidelines, and a simple, rapid, sensitive, stable, and highly effective RP-HPLC method for their determination was developed. This article includes the results of validation experiments on the solubility, wavelength, optimization of chromatographic conditions, linearity, and system suitability of the proposed technique for quantification of both medications. The chosen analytes were successfully quantified from the tablet formulation using the method. Since this procedure does not cause any problems due to chemicals, etc., it would be useful to apply it to the development of other medications.

Nebivolol HCL, Telmisartan, and RP-HPLC Validation are some key phrases

introduction

The research, creation, standardization, and quality control of pharmaceuticals and medical equipment all depend on analytical methods. Although just a first effort was undertaken in this study, validated analytical techniques for the determination of a single or mixed dose form have been developed. Calculating the amount of degradation products produced during formulation and storage of a product utilizing methods like as The diffusion process governs the phase. Diffusion minimization allows for a more rapid and efficient separation to take place. Some examples of such characteristics include solubility,

maximum shift, absorbance overlap, etc. But today, thanks to a plethora of high-tech analytical tools, we can overcome these obstacles. (2,4) UV-Visible Spectrophotometer, HPLC, HPTLC also UPLC (points 1-3). Gradient elution may be achieved by progressively adjusting the solvent content. Rate of dispersal between fixed and mobile The various methods of analysis can be broadly classified into two categories; Classical methods and Instrumental methods,

St. Theresa's women college ,Department of Biological Science A.P

UV-Visible spectrophotometry, High performance liquid chromatography (HPLC) and High performance thin layer chromatography (HPTLC) are the most widely used techniques (2,4,5). Chromatography may be defined as a method of separating a mixture of components into individual components through equilibrium distribution between two phases that is mobile phase and stationary phase(6). HPLC is the method of choice for checking peak purity of new chemical entities, monitoring reaction changes in synthetic procedures or scale up, evaluating new formulations and carrying out quality control / assurance of the final drug products(7). The essential parts of the High Performance Liquid Chromatography are, Solvent reservoir and Treatment system, Mobile phase, Pump system, Sample Injection System, Column, Detector, Recording and interpretation unit. The most widely used detector in HPLC is the UV- absorption or spectrophotometer. In this detector the changes in UV-absorption when the solution passes through a flow cell is measured. UV detectors are concentration sensitive and have the advantage that they don't destroy the solute. UV detection can utilize the fixed emission line of a mercury

line (254 nm) to allow the detection of molecules with some absorption at this wavelength. The continuous emission of energy by deuterium lamp can be utilized in conjunction with a monochromator to provide a variable wavelength detector. Double beam UV detectors are available which can record the spectrum if the flow is stopped; while the solute passes through cell. Not all molecules possess sufficiently strong UV chromophore for satisfactory UV absorption. Bile acids, lipids, sugars etc., are examples of such compounds (4,5).

Validation of an analytical method is the "A documented programme, which provides a high degree of assurance that a specific process will consistently produce, a product meeting its pre- determined specifications and quality attributes" (4,5). The following are typical analytical performance characteristics which may be tested during methods validation, Accuracy, Precision, Repeatability, Intermediate precision, Linearity,

Specificity, Range, Robustness System suitability determination (2,3,4,6).




fig. 1: Instrumentation of HPLC

Material and Methods

Nebivolol HCL, Telmisartan from Lupin Research park, Methanol (HPLC grade), Distilled Water (HPLC grade), Ortho Phosphoric Acid (HPLC grade) from Merck Ltd. India, UV-Visible Spectrophotometer model 2080, HPLC Agilent 1100, pH Meter Sytonic Sy-614A, Balance

CY 104 (Micro Analytical Balance), Ultrasonicator Meta-lab 1.5 L 50 were used.

Optimization of chromatographic condition The mobile phase was prepared by methanol & 0.1% OPA acid having pH-7 (80:20% v/v). To take 400ml of methanol and 100ml of 0.1% OPA acid having pH-7. Figure 3,4,5. To take 10mg of Nebivolol HCL and 80mg Telmisartan dissolved in 10ml methanol. Add 1 drop of tri-ethylamine

and Sonicated for 10mins. And take 0.2ml from stock solution and dissolved in 10ml mobile phase. This solution holds 20ppm. Of Nebivolol HCL & 80ppm Telmisartan. Table 1,2,3,4. (13,14) Linearity

Accurately weighed Nebivolol HCL 5mg and Telmisartan 40mg dissolved in 10 ml Methanol. (15,16) And add 1 drop tri-ethylamine. And sonicate for 10min. This solution holds 500µg/ml of Nebivolol HCL and 4000µg/ml of Telmisartan. Take 0.1ml from above solution dissolved in 10ml mobile phase. For linearity study to take 10µg/ml, 20µg/ml, 30µg/ml, 40µg/ml & 50µg/ml sample are prepared. And inject to record the chromatogram of linearity. (17,18,19,20)

Accuracy

Recovery studies were performed to validate the accuracy

f developed method. To pre analysed tablet solution, a definite concentration of standard drug (80%, 100%, and 120%) was added and then its recovery was analysed. Statistical validation of recovery studies shown in Table no.7. Specificity was measured as ability of the proposed method to obtain well separated peaks for Nebivolol HCL and Telmisartan without any interference from component of matrix. Shown in Table no. 12,13, Figure 7,8. (23,24,25) Robustness

The Robustness of a method is its ability to remain unaffected by small deliberate changes in parameters. (26) To evaluate the robustness of the proposed method, small but deliberate variations in the optimized method parameters were done. The effect of changes in mobile phase composition and flow rate on retention time and tailing factor of drug peak was studied. The mobile phase composition was changed in ± 1 ml proportion and the flow rate was varied by ± 0.1 ml min⁻¹, of optimized chromatographic condition. (27,28) The results of robustness studies are shown in Table No.14 &15. System suitability parameters were also found satisfactory; hence the analytical method would be concluded. Results and Discussion Selection of wavelength This solution is scan by Uv-visible spectrophotometer under a scanning wavelength 200nm-400nm. The wavelength of Nebivolol HCL & Telmisartan was found to be 286nm. And hence this wavelength is used for method development purpose. As show in Fig.2




Fig. 2: UV-visible spectra. of Nebivolol HCL & Telmisartan

Selection of mobile phase





Fig. 3: chromatogram of Trail-1 Table 1: Detail of chromatogram of Trail-1

Sr.No	Drug	Rt time	Area	Plates	Symmetry
-------	------	---------	------	--------	----------

Fig.4: Chromatogram of Trail-2 Table 2: Detail of chromatogram of Trail-2



**Fig. 5: Chromatogram of Trail-3
Table 3: Detail of chromatogram of Trail-3**

Sr.No	Drug	Rt time	Area	Plates	Symmetry
1.	TEL	3.004	4418.68	4812	0.99
2.	NEB	5.469	361.86	6460	0.80



Fig. 5: Chromatogram of Trail-3
Table 3: Detail of chromatogram of Trail-3

Sr.No	Drug	Rt time	Area	Plates	Symmetry
1.	TEL	3.004	4418.68	4812	0.99
2.	NEB	5.469	361.86	6460	0.80

Table No 4: Showing result of Experimental Trials

Trial	Column used	Mobilephase, Rate and Wavelength	Inj. Vol.	Observation	Conclusion
1	C ₁₈ (AGILENT) (250×4.6mm)	Methanol & 0.1% OPA acid (90:10% v/v). Rate=0.7ML, Wavelength-286nm(pH-3)	20 μ l	Well resolved peaks were not obtained	Hence rejected
2	C ₁₈ (AGILENT) (250 ×4.6mm)	80% Methanol: 20% Water (0.1 % OPA) Flow rate 0.7 ml. Wavelength-286nm(pH-3)	20 μ l	Well resolved peaks were not obtained	Hence rejected
3	C ₁₈ (AGILENT) (250 ×4.6mm)	80% Methanol: 20% Water (0.1 % OPA) Flow rate 0.7 ml. Wavelength-286NM (pH-7)	20 μ l	Well resolved peaks were obtained	Hence selected

Linearity study


Linearity of Nebivolol was observed in the range of 10-50 μ g/ml and Telmisartan was observed in 0.9996 for Nebivolol and Telmisartan respectively.

the range of 10-50 μ g/ml Detection of wavelength used was 286 nm. The calibration curve yielded correlation coefficient (r^2) 0.9999 &

As per Table no.5 and Figure no. 6.

Table 5: Result of standard calibration curve for Nebivolol HCL

Sr No.	Conc	Area I	Area II	Mean	SD	%RSD
1	40	79.71	80.23	79.97	0.37	0.46



2	80	162.3	161.21	161.76	0.77	0.48
3	120	245.13	248.61	246.87	2.46	1.00
4	160	325.89	328.86	327.38	2.10	0.64
5	200	407.99	406.93	407.46	0.75	0.18
		$R^2=0.9999$	$M=16.40$	$C=1.284$	$Avg=1.29$	$Avg=0.55$

Fig. 6: Standard Calibration Curves for Nebivolol HCLSystem suitability test

System suitability was performed to verify, whether the resolution and reproducibility of the chromatographic system are adequate. Table 6: Result of system suitability for Nebivolol HCL and Telmisartan

Sr. No.	Peak area		Retention Time		Asymmetry		Theoretical plates	
	NEB	TEL	NEB	TEL	NEB	TEL	NEB	TEL
1	244.21	6280.86	5.69	3.04	0.75	0.91	7135	5587
2	243.32	6295.31	5.67	3.03	0.46	0.91	7090	5425
3	244.10	6270.15	5.68	3.05	0.55	0.92	7145	5547
4	242.15	6285.25	5.66	3.06	0.67	0.94	7065	5326

5	245.17	6291.26	5.70	3.07	0.71	0.93	7180	5598
Mean	243.79	6284.56	5.68	3.05	0.62	0.92	7123	5497
S. D	1.12	9.77	0.01	0.01	0.01	0.01	45.63	117.50
C.V	0.45	0.15	0.17	0.32	1.61	1.08	0.64	2.13

Accuracy

Accuracy of method is ascertained by recovery studies performed at different levels of

concentrations (80%, 100% and 120%). The % recovery was found to be within 99.52-100.99 %. As per table no.7



Table 7: Statistical Validation of Recovery Studies.

Level of Recovery (%)	Drug	Mean Recovery %	Standard Deviation	% RSD
80	Nebivolol HCL	100.54	0.65	0.44
	Telmisartan	99.70	6.33	0.17
100	Nebivolol HCL	100.99	0.58	0.35
	Telmisartan	99.52	7.06	0.17
120	Nebivolol HCL	100.1	0.49	0.27
	Telmisartan	99.54	0.96	0.23

Precision

Precision studies were carried out using parameter like intra-day and inter-day precision, the study showed that the results were within acceptance limit. i.e. %RSD below 2.0 indicating reproducibility of method. Results as shown in following table no.8,9,10,11.

Result of Intraday Telmisartan

Table 8: Intra-day Precision study Telmisartan

Sr No.	Conc	Area-I	Area-II	Mean	Amt Found	% Amt Found	SD	%RSD
1	80	4165.59	4168.69	4167.14	79.30	99.13	0.96	0.02
2	120	6290.41	6292.61	6291.51	120.79	100.65	1.56	0.02
3	160	8391.47	8386.03	8388.75	161.74	101.09	3.85	0.04

Result of Intraday Nebivolol HCL

Table 9: Intra-day Precision study Nebivolol HCL

Sr No.	Conc.	Area-I	Area-II	Mean	Amt Found	% Amt Found	SD	%RSD
1	10	161.55	168.69	165.12	10.14	101.46	0.96	0.58
2	15	239.03	234.09	236.56	14.82	98.85	3.49	1.47
3	20	328.8	322.19	325.50	19.92	99.60	4.67	1.43

Interday Telmisartan

Table 10: Interday Telmisartan study



Sr No.	Conc.	Area-I	Area-II	Mean	Amt Found	% Amt Found	SD	%RSD
1	80	4166.32	4168.87	4167.60	79.31	99.14	0.96	0.02
2	120	6287.74	6291.11	6289.43	120.75	100.62	2.38	0.03
/3	160	8389.15	8392.55	8390.78	161.78	101.11	2.51	0.02

**Interday Nebivolol
HCL**

Table 11: Interday Nebivolol HCL study

Sr No.	Conc.	Area-I	Area-II	Mean	Amt Found	% Amt Found	SD	%RSD
1	10	161.23	165.78	163.51	10.04	100.40	0.96	0.58
2	15	241.52	242.91	242.22	14.84	98.93	0.98	0.40
3	20	330.09	326.5	328.30	20.09	100.45	2.54	0.77

Specificity

API and the Tablet sample solution prepared as per the proposed method to check for the interference if any peak at the retention time of Nebivolol and Telmisartan. Thus, no interference was found at the Retention time of Nebivolol and Telmisartan which is 3.00 & 5.46min respectively, Shown in Figure no. 7 and 8, Table no.12,13.




Fig. 7: A chromatogram of API




Fig. 8: A chromatogram of Tablets

Table 12: Detail of chromatogram of API

<u>Sr.No</u>	<u>Drug</u>	<u>Rt time</u>	<u>Area</u>	<u>Plates</u>	<u>Symmetry</u>
1.	TEL	3.062	8395.49	5247	0.96
2.	NEB	5.737	325.86	7255	0.75

Table 13: Detail of chromatogram of Tablets

<u>Sr.No</u>	<u>Drug</u>	<u>Rt time</u>	<u>Area</u>	<u>Plates</u>	<u>Symmetry</u>
1.	TEL	3.036	8380.08	5287	0.90
2.	NEB	5.677	326.68	7250	0.53

Robustness

To evaluate the robustness of the method, the parameters selected were varied at three levels.

The results indicate that less variability in retention time and tailing factor were observed in following table no. 14,15.



Table 15: Result of Robustness Study of Telmisartan

Parameters ^{4. Jeffery}	Conc. (µg/ml)	MEAN	SD	%RSD
Mobile phase composition-(81+19)	40	8122.17	15.98	0.20
Mobile phase composition-(79+21)	40	8372.90	24.72	0.73
Wavelength change 285nm	40	8111.70	21.96	0.27
Wavelength Change 287nm	40	8044.71	70.59	0.88
Flow rate change(0.9ml)	40	9134.71	17.41	0.19
Flow rate change(1.1ml)	40	7531.67	111.45	1.48

The analysis of tablet formulation was done and the results obtained within the limits. The results obtained for validation study were within the limit specified by the ICH guidelines and hence the method was found to be linear, precise. The results of recovery study were within ICH limits, thus indicating the accuracy of method. The present work involved the development of accurate, precise, and simple suitable RP-HPLC method for estimation of the drugs in multicomponent tablet formulation. Method successfully quantified the selected analytes from tablet formulation. No interference of additives etc. is encountered in this method further studies on other pharmaceuticals formulation would throw more light on those study.

Conclusion

All of the method validation parameters were fulfilled, demonstrating the technique's overall success. For the purpose of routine determination of Telmisartan and Nebivolol HCL, this approach is suitable for implementation.

References

REFERENCE

1. A. A.H. et al. (2002). Practical pharmaceutical chemistry, London. A&C black publication: 163-164.
2. Rouessac F. and Rouessac A. (1998). Chemical analysis Modern Instrumental method and technique, France. John Wiley & Sons Ltd: 63-68.

Skoog D.A. and West D.M. (1996). Principles of instrumental analysis,

U.S.A. Saunders college publication: 2-3.H., Basset J., Mendham J. and Denney

R.C. (1989). Vogel's textbook of quantitative chemical analysis, London. Longman Group UK Ltd: 3.

Rashmin., An Introduction to analytical method development for pharmaceutical formulation, at

<http://www.pharmainfo.net>.

Panchumathy R., Naga Navya., Pravallika D., Navya D. and Sri A. (2015). Review on Step-by-Step Analytical Method Validation, IOSR Journal Of Pharmacy, 5(10): 07-19.



Gurdeep R., Chatwal., Sham K. and Anand.(2005).Instrumental methods of chemical analysis, 5th edition, Mumbai,Delhi, Bangalore, Nagpur, Hyderabad: Himalaya Publishing House: 2.566-8, 2.626-8.

Burgess C.(2001). Validation of Analytical Methods & Procedures, 1st edition, Royal Society of Chemistry, UK: 4-41.

Synder L.,Kirland R., GlajchJ. (1997). Introduction to Modern Liquid Chromatography, 2nd edition, Wiley Inter science, New York: 5-42.

Cazes, Scott R.,MarcelD. (2002). Chromatography Theory, 10th edition, Inc., New York: 4-45.

Braithwaite Smith,.(1999). Chromatography Methods, 5th edition, Kluwer Academi Publishers, USA:2-43.

Nidhal M., Sher M.,Hasan A. and Hassan M.(2019). Reported method development and validationof

simultaneousdetermination of hydrochlorothiazide and losartan in tablet